

14°

CONGRESSO NAZIONALE SINut

SINut
Società Italiana di Nutraceutica

12-14 settembre 2024

Bologna



BRAIN LONGEVITY: I RIMEDI VENGONO DAL MARE




Giovanni Scapagnini

Dipartimento di Medicina e Scienze della Salute
«V. Tiberio», Università degli Studi del Molise


Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019

GBD 2019 Dementia Forecasting Collaborators*


The number of people with dementia would increase from 57·4 (95% uncertainty interval 50·4–65·1) million cases globally in 2019 to 152·8 (130·8–175·9) million cases in 2050



Studies included in review
(n = 15) 55
Total Persons n= 47,910
Long-Term COVID19 effects



Xue Cao^{1,2,3}, Wenjuan Li⁴, Ting Wang⁵, Dongzhi Ran^{6,7}, Veronica Davalos⁸, Laura Planas-Serra^{9,10}, Aurora Pujol^{9,10,11}, Manel Esteller^{8,11,12,13}, Xiaolin Wang² & Huichuan Yu^{2,3}✉





Accelerated epigenetic aging is associated with the risk of SARS-CoV-2 infection and developing severe COVID-19. In addition, the accumulation of epigenetic aging from COVID-19 may contribute to the post-COVID-19 syndrome among survivors.


COVID-19 lockdown effects on adolescent brain structure suggest accelerated maturation that is more pronounced in females than in males

Neva M. Corrigan ^{a,b}, Ariel Rokem ^{b,c,d}, and Patricia K. Kuhl ^{a,e,1}

Contributed by Patricia K. Kuhl; received February 27, 2024; accepted July 26, 2024; reviewed by Russell T. Shinohara and Leah H. Somerville





September 9, 2024 | 121 (38) e2403200121





Alzheimer's disease drug development pipeline: 2023


2023 Alzheimer's Drug Development Pipeline




Toward defining the preclinical stages of Alzheimer's disease:

Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup

The continuum of Alzheimer's disease




Nikolaos Scarmeas, Costas A Anastasiou, Mary Yannakoulia



Nutrients related to cognitive function

Nutrition for the ageing brain: Towards evidence for an optimal diet

Vauzour D, et al. 2016



Overview of links between lifestyle interventions on cognition and healthy brain function during ageing.


science & society

‘Positive biology’ as a new paradigm for the medical sciences


Focusing on people who live long, happy, healthy lives might hold the key to improving human well-being

Colin Farrelly

Eliminating all types of cancer would increase life expectancy in the USA by approximately only three years



BLUE ZONES – GEOGRAPHY OF LONGEVITY



LONGEVITY HOTSPOTS

LOMA LINDA
CALIFORNIA

NICOYA
COSTA RICA

SARDINIA
ITALY

ICARIA
GREECE

OKINAWA
JAPAN

BLUE ZONE LIFE LESSONS



MOVE NATURALLY





RIGHT TRIBE



RIGHT OUTLOOK




EAT WISELY



Sources: Yamada, M., et al. J Am Geriatr Soc 1999;47:189-95.
 Kokmen, E., et al. Mayo Clin Proc 1996;71:275-82. Ogura, C., et al.
 Internat J Epidemiol 1995;24:373-80.


Healthy aging diets other than the Mediterranean: A focus on the Okinawan diet

Donald Craig Willcox^{a,b,c,*}, Giovanni Scapagnini^d, Bradley J. Willcox^{b,c}



Key Features of Traditional Okinawa Diet


- 1) Low Caloric Density (plant-based, low fat, moderate protein from soy, fish, lean meats)
- 2) High Nutrient Density (Vitamins A,C, E, potassium, magnesium, folate, and healthy oils)
- 3) Phyto-nutrient Rich (polyphenols, carotenoids mostly from green leafy, yellow root vegetables and seaweed)
- 4) Low in Glycemic Load (high quality carbohydrates from staple sweet potato)
- 5) Anti-inflammatory (CR, polyphenols, omega 3 fatty acids)



Traditional Okinawan diet food pyramid


Healthy aging diets other than the Mediterranean: A focus on the Okinawan diet.
Willcox DC, Scapagnini G, Willcox BJ. Mech Ageing Dev. 2014 Jan 21.

Turmeric
Curcuma longa




Curcumin

Ipomea batatas
cultivar *Ayamurasaki*



Anthocyanin



Wakame
Undaria pinnatifida



Phlorotannin

Traditional Food Items in Ogimi, Okinawa: L-Serine Content and the Potential for Neuroprotection

Paul Alan Cox¹ • James S. Metcalf¹

















Breeding techniques




Extraction techniques

- Microwave-assisted extraction (MAE)
- Ultrasound-assisted extraction (UAE)
- Supercritical fluid extraction (SFE)
- Pressurized solvent extraction (PSE)
- Enzyme-assisted extraction (EAE)



Applications




The Epic of Gilgamesh
Written in Mesopotamia 2000 BC





“King Gilgamesh, you wish to live forever. There is a plant that grows under the sea. This seaweed will restore your health and strength. It contains the secret of eternal youth”



Bioactive compounds from marine seaweeds




Natural Bioactive Compounds from Macroalgae and Microalgae for the Treatment of Alzheimer’s Disease: A Review




Review

Potential Application of Marine Algae and Their Bioactive Metabolites in Brain Disease Treatment: Pharmacognosy and Pharmacology Insights for Therapeutic Advances




Fucoidan Mechanism



Edible seaweed-derived constituents: an undisclosed source of neuroprotective compounds



NEURAL REGENERATION RESEARCH, 2020

Melissa Schepers^{1,2,#}, Nikita Martens^{3,#}, Assia Tiane^{1,2}, Kenneth Vanbrabant^{1,4}, Hong-Bing Liu⁵, Dieter Lütjohann⁴, Monique Mulder^{3,#}, Tim Vanmierlo^{1,2,*,#}



Article


Acute Post-Prandial Cognitive Effects of Brown Seaweed Extract in Humans



The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review

Carlo Caltagirone¹, Luigi Ferrannini², Niccolò Marchionni³, Giuseppe Nappi⁴, Giovanni Scapagnini⁵ and Marco Trabucchi⁶


¹Chair of Neurology, University of Roma Tor Vergata, and Scientific Director, IRCSS Santa Lucia Foundation, Rome, ²Department of Mental Health and Addictions - ASL 3 Genoa, and President of the Italian Psychiatry Association, ³Division of Geriatric Cardiology and Medicine, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, ⁴Scientific Director, IRCCS "C. Mondino National Neurological Institute", Pavia, and Chair of Neurology, University "La Sapienza", Rome, ⁵Department of Health Sciences, Faculty of Medicine and Surgery, University of Molise, Campobasso, ⁶Geriatric Research Group, Brescia, Italy



- Homotaurine (Tramiprosate)



Homotaurine Inhibits Formation of Toxic Amyloid Fibrils *in vitro*



Amyloid A β




Amyloid A β + homotaurine

24-hour incubation


Homotaurine Reduces Amyloid Deposition in hAPP Transgenic Mouse Brain

Control (untreated)




Homotaurine (100mg/kg/day)

(8 weeks of treatment)



GABA_A receptors as plausible molecular targets and mediators for taurine and homotaurine actions


Pratap Meera ¹, Mikko Uusi-Oukari ²,
Gerald S. Lipshutz ^{3,4,5,6*} and Martin Wallner ^{3*}




16 Clinical Trials Involving > 2,000 Subjects

| Studies | N | Population | Duration | Endpoints |
|--|-------|-----------------------------------|-----------|--|
| 10 Phase I | 288 | Healthy | 7-10 days | Safety/PK |
| Phase II | 58 | AD | 3 months | Cognitive function, Amyloid A β CSF level |
| Phase II Open-label extension | 42 | AD | 41 months | Cognitive function |
| Phase II | 24 | Cerebral Amyloid Angiopathy | 3 months | Neurological function, cognitive function |
| Phase III North America | 1,052 | AD | 18 months | Cognitive function, brain volume |
| Phase III North America Open-label extension | 738 | AD | 12 months | Cognitive function |
| Phase III Europe | 975 | AD | 18 months | Cognitive function, brain volume |

Homotaurine Reduces Cognitive Decline Significantly in AD Patients - ApoE4+




Homotaurine Preserved Brain Volume by 68% vs. Control in AD Patients



RESEARCH ARTICLE


APOLLOE4 Phase 3 study of oral ALZ-801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer’s disease: Trial design and baseline characteristics



This Red Color is **Astaxanthin**



Astaxanthin the Most Powerful Natural Antioxidant




Review

Astaxanthin in Skin Health, Repair, and Disease: A Comprehensive Review

Sergio Davinelli ^{1,*} , Michael E. Nielsen ²  and Giovanni Scapagnini ¹


Table 1. Summary of human intervention studies on skin and astaxanthin.


| Intervention | Study Design | Control | Population (n) | Duration | Outcomes | Dosage | Author, Year |
|--|--|---------|---|----------|--|----------------------------------|-----------------|
| Administration of ASX capsules | Randomized double-blind, controlled study | Placebo | Healthy female subjects (14/diet group) | 8 weeks | ↓ DNA damage biomarkers; ↑ of NK cells, T cells, B cells, and IL-6 | 2 or 8 mg | Park, 2010 |
| Administration of ASX capsules | Monitoring of oxidative stress and skin aging | None | 31 middle-aged volunteers | 4 weeks | ↓ MDA; ↓ RSSC | 4 mg | Chalyk, 2017 |
| Administration of ASX capsules | Randomized, double-blind, parallel-group, placebo-controlled | Placebo | 65 healthy female subjects | 16 weeks | ↓ Wrinkle parameters; ↓ IL-α | 6 or 12 mg | Tominaga, 2017 |
| Administration of ASX cream | Pilot study | None | 3 healthy female subjects | 2 weeks | ↓ Wrinkle parameters | 0.7 mg/g of ASX cream | Seki, 2001 |
| Topical application of ASX | Pilot study | None | 3 healthy male subjects | N/S | ↓ erythema | N/S | Yamashita, 1995 |
| Administration of ASX capsules | Randomized, single-blind, placebo-controlled | Placebo | 49 healthy female subjects | 6 weeks | ↓ Wrinkle parameters | 2 mg | Yamashita, 2006 |
| Oral and topical treatment with ASX | N/S | N/S | 28 healthy female subjects | 8 weeks | ↓ Wrinkle parameters | 6 mg | Tominaga, 2009 |
| Two oral forms (ASX capsules; tablets collagen) | Randomized, double-blind placebo-controlled | Placebo | 44 healthy female volunteers | 12 weeks | ↑ viscoelastic parameters; ↓ TEWL; ↑ procollagen type I; ↓ MMP-1 and MMP-12 | 2 mg | Yoon, 2014 |
| Capsules of ASX combined with topical application of ASX | Open-label noncontrolled | None | 30 healthy female subjects | 8 weeks | ↓ wrinkles; ↓ age spot size; ↑ elasticity; ↑ skin texture | 6 mg and 2 mL (78.9 μM solution) | Tominaga, 2012 |
| Administration of ASX capsules | Randomized double-blind controlled | Placebo | 36 healthy male subjects | 6 weeks | ↓ wrinkles; ↑ elasticity; ↓ TEWL; ↑ moisture content; ↓ sebum oil | 6 mg | Tominaga, 2012 |



Astaxanthin as a Modulator of Nrf2, NF- κ B, and Their Crosstalk: Molecular Mechanisms and Possible Clinical Applications


Molecules 2022, 27, 502.


Sergio Davinelli ^{1,*} , Luciano Saso ² , Floriana D'Angeli ³ , Vittorio Calabrese ³ , Mariano Intrieri ¹ and Giovanni Scapagnini ¹ 




Astaxanthin as a Modulator of Nrf2, NF- κ B, and Their Crosstalk: Molecular Mechanisms and Possible Clinical Applications

Sergio Davinelli ^{1,*}, Luciano Saso ², Floriana D'Angeli ³, Vittorio Calabrese ³, Mariano Intrieri ¹ and Giovanni Scapagnini ¹






Astaxanthin enhances autophagy, amyloid beta clearance and exerts anti-inflammatory effects in *in vitro* models of Alzheimer's disease-related blood brain barrier dysfunction and inflammation




ASX reduces protein expression of APP/Aβ as well as increases expression of genes involved in Aβ clearance in Aβ-treated pBCECs.

Supplemental Cellular Protection by a Carotenoid Extends Lifespan via Ins/IGF-1 Signaling in *Caenorhabditis elegans*

Koumei Yazaki, Chinatsu Yoshikoshi, Satoru Oshiro, and Sumino Yanase



Localization of DAF-16/FOXO : GFP





AX-containing NGM plates for measurement of lifespan in nematode


Astaxanthin as a Putative Geroprotector: Molecular Basis and Focus on Brain Aging



marine drugs


Mar. Drugs 2020, 18, 351

Vincenzo Sorrenti ^{1,2,*} , Sergio Davinelli ³ , Giovanni Scapagnini ³, Bradley J. Willcox ^{4,5}, Richard C. Allsopp ⁶ and Donald C. Willcox ^{4,5,7}




C2019: Astaxanthin

“Anti-oxidant” – Brad Willcox and Richard Allsopp
OTC for human use



12% increase in median
 $p = 0.003$



3% increase in median
 $p = 0.6$



Healthy Longevity




Yong Loo Lin
School of Medicine





RESEARCH ARTICLE

Astaxanthin supplementation enhances adult hippocampal neurogenesis and spatial memory in mice


Jang Soo Yook¹, Masahiro Okamoto¹, Randeep Rakwal², Junko Shibato¹, Min Chul Lee^{1,3}, Takashi Matsui¹, Hyukki Chang⁴, Joon Yong Cho⁵ and Hideaki Soya¹



Dietary Astaxanthin: A Promising Antioxidant and Anti-Inflammatory Agent for Brain Aging and Adult Neurogenesis

Alessandro Medoro ¹, Sergio Davinelli ¹, Luigi Milella ², Bradley J. Willcox ^{3,4}, Richard C. Allsopp ^{3,5}, Giovanni Scapagnini ^{1,*} and Donald Craig Willcox ^{3,4,6}

The unique chemical structure of astaxanthin enables it to cross the blood–brain barrier and easily reach the brain, where it may positively influence adult neurogenesis. Astaxanthin can affect molecular pathways involved in the homeostasis, through the activation of FOXO3-related genetic pathways, growth, and regeneration of adult brain neurons, enhancing cell proliferation and the potency of stem cells in neural progenitor cells.






Review


Carotenoids and Cognitive Outcomes: A Meta-Analysis of Randomized Intervention Trials

Sergio Davinelli ^{1,*} , Sawan Ali ¹, Vincenzo Solfrizzi ², Giovanni Scapagnini ¹ and Graziamaria Corbi ¹


In conclusion, these results highlight the potential role of carotenoids in the protection of mental functions even in subjects without cognitive impairment.





OMEGA 6



linoleic acid
LA




gamma linolenic acid
GLA




arachidonic acid
AA


OMEGA 3




alpha linolenic acid
ALA




eicosapentaenoic acid
EPA



docosahexanoic acid
DHA



Dietary omega-3 fatty acids can affect synaptic plasticity and cognition.



Performance & Learning

BEFORE

to pay Mrs Twit back
for the worms in his
spaghet Mr Twit thought
up a really clever trick

A six year old child's handwriting
on a Junk Food diet.

AFTER

To pay Mrs Twit back
for the worms in his
spagetti Mr Twit thought
up a really clever trick

Six year old child's handwriting
after one month of *change in diet.

Adherence to a Mediterranean diet and cognitive function in the Age-Related Eye Disease Studies 1 & 2

Tiarnán D. Keenan, Elvira Agrón, Julie A. Mares, Traci E. Clemons, Freekje van Asten, Anand Swaroop, Emily Y. Chew✉, for the AREDS and AREDS2 Research Groups

7,756 participants enrolled in two randomized trials of nutritional supplements for age-related macular degeneration: Age-Related Eye Disease Study (AREDS) and AREDS2.

Closer Mediterranean diet adherence was associated with lower risk of cognitive impairment but not slower decline in cognitive function.



Fish intake was associated with higher cognitive function. In AREDS2, rate of cognitive decline over 5 to 10 years was not significantly different by a MED but was significantly slower ($P = .019$) with higher fish intake.



HHS Public Access

Author manuscript

Prostaglandins Leukot Essent Fatty Acids. Author manuscript; available in PMC 2018 June 15.

Published in final edited form as:


Prostaglandins Leukot Essent Fatty Acids. 2017 June ; 121: 68–75. doi:10.1016/j.plefa.2017.06.006.

Erythrocyte omega-3 fatty acids are inversely associated with incident dementia: Secondary analyses of longitudinal data from the Women's Health Initiative Memory Study (WHIMS)


Eric M. Ammann, PhD^a, James V. Pottala, PhD^b, Jennifer G. Robinson, MD MPH^{a,c}, Mark A. Espeland, PhD^d, and William S. Harris, PhD^{b,e,*}

Highlights

- We examined the association between erythrocyte EPA+DHA and risk for incident dementia in 6706 women in the USA.
- After about 10 years of follow-up and after appropriate adjustments, we found a significant, 8% decreased risk for probable dementia associated with a 1-SD increase in EPA+DHA.
- This large study confirms previous research suggesting that higher EPA+DHA levels may be protective against dementia.




Inflammatory response and resolution time course: Roles of pro-resolving lipid mediators.



Role of phosphatidylcholine-DHA in preventing APOE4-associated Alzheimer's disease


Rhonda P. Patrick¹



AD is associated with decreased GLUT1 transporters and glucose uptake, tau tangles inside of neurons, and amyloid- β plaques in the extracellular space between neurons.

DHA regulates brain glucose uptake, which prevents amyloid- β plaque and tau tangle formation


Low DHA concentrations in the brain reduce GLUT1 transporter expression, which leads to increased tau phosphorylation and promotes amyloid- β plaque formation.



Research paper

Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial

Isabella C. Arellanes^{a,1}, Nicholas Choe^{a,1}, Victoria Solomon^{a,1}, Xulei He^a, Brian Kavin^a, Ashley E. Martinez^a, Naoko Kono^b, David P. Buennagel^c, Nalini Hazra^d, Giselle Kim^d, Lina M. D'Orazio^e, Carol McCleary^e, Abhay Sagare^f, Berislav V. Zlokovic^f, Howard N. Hodis^{a,b}, Wendy J. Mack^b, Helena C. Chui^e, Michael G. Harrington^{c,e}, Meredith N. Braskie^d, Lon S. Schneider^{e,g}, Hussein N. Yassine^{a,e,*}



Added value of this study



In this placebo-controlled trial, cognitively unimpaired adults were provided with a vitamin B complex and randomized to 2 gs per day of DHA supplementation or placebo over 6 months. A modest increase in cerebrospinal fluid (CSF) DHA levels was observed following supplementation, with *APOE4* carriers having a lower increase than non-carriers.

Implications of all the available evidence

Dementia prevention trials that use omega-3 doses of equal or less than 1 g per day may have reduced brain effects, and especially for *APOE4* carriers.

Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia

H.N. Yassine^{1,2}, I.C. Arellanes¹, A. Mazmanian¹, L. De La Cruz¹, J. Martinez¹, L. Contreras¹, N. Kono³, B.S. Liu¹, D. Badie¹, M.A. Bantugan¹, A. Grindon¹, T. Urich¹, L. D'Orazio², B.A. Emmanuel², H.C. Chui², W.J. Mack³, M.G. Harrington², M.N. Braskie⁴, L.S. Schneider⁵





LO-MAPT STUDY

*Making dementia a priority:
changing perceptions, practice and policy.*

Study Design

Clinicaltrials.gov
identifier

NCT03691519

Study Type ⓘ : Interventional (Clinical Trial)

Actual Enrollment ⓘ : 774 participants

Allocation: Randomized

1. Study Information

| | |
|-------------------|---|
| Name of the study | Prevention of cognitive decline in older adults with low Dha/Epa index in red blood cells |
| Study sponsor | University Hospital, Toulouse |
| Disease | At risk of developing Alzheimer's disease |
| Phase | Phase III |

2. Information about the drug that will be tested in the study

| | |
|----------------|-------------------------------------|
| Name of drug | Omega-3 |
| Administration | Three capsules taken orally per day |



FRANCESCO CINELLI
GIOVANNI SCAPAGNINI

L'EDEN SOMMERSO

VIAGGIO NELLA SCIENZA DELLE ALGHE:
ALIMENTAZIONE,
LONGEVITÀ E SOSTENIBILITÀ

MONDADORI

